Quest Diagnostics company, medical laboratory operator said Tuesday that its board of directors increased by $ 100 million share repurchase program.
This brings the total amount of its share repurchase program to $ 1.3 billion.
Quest Diagnostics Company will use its drug candidate ibrutinib right to repurchase shares of the net proceeds of sale of $ 30 billion, the company's CEO and President Steve Rusckowski said in a statement.
, Headquartered in Madison, New Jersey, the company's stock rose 21 cents to close at $ 58.76 on Tuesday. Shares were up nearly 2% boost buyback program announced in after-hours trading.
 



Other News:
Colombia's Santos seeks referendum to pave way for peace deal
NSA collected 56,000 emails by Americans a year: documents
Quest Diagnostics increases buyback by $1 billion
U.N. peacekeepers in Congo ordered to protect civilians after city shelled
Stock futures rise after 4-day sell-off
Google and NFL meet; Sunday Ticket up for grabs?
Malaysia cuts GDP forecast in sign of Asia stress
Glencore profit hit by $7.6 billion Xstrata charge